This content is machine translated Precision therapy Targeted MET inhibition after progression with osimertinib Despite the success of osimertinib, a third-generation EGFR-TKI, in first-line therapy, the treatment of NSCLC after progression remains a challenge. SAVANNAH and ORCHARD have investigated the targeted addition of additional...…
